TransMedics Group, Inc. (NASDAQ:TMDX) Insider Tamer I. Khayal Sells 1,084 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

TransMedics Group Trading Up 1.1 %

TMDX stock traded up $0.77 on Wednesday, reaching $72.21. The company’s stock had a trading volume of 2,417,077 shares, compared to its average volume of 1,023,110. The firm has a market cap of $2.42 billion, a PE ratio of 76.00 and a beta of 2.06. The business has a fifty day simple moving average of $108.52 and a two-hundred day simple moving average of $135.34. TransMedics Group, Inc. has a 12-month low of $68.84 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, research analysts forecast that TransMedics Group, Inc. will post 1.01 EPS for the current year.

Analyst Ratings Changes

TMDX has been the topic of a number of recent research reports. Piper Sandler dropped their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday. TD Cowen cut their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Robert W. Baird lowered their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $131.80.

Institutional Trading of TransMedics Group

Large investors have recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group in the 2nd quarter valued at approximately $47,000. USA Financial Formulas purchased a new stake in TransMedics Group in the third quarter worth $55,000. Quarry LP raised its holdings in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI lifted its position in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares during the period. Finally, J.Safra Asset Management Corp boosted its holdings in shares of TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.